PT  - JOURNAL ARTICLE
AU  - Kazerooni, Anahita Fathi
AU  - Kraya, Adam
AU  - Rathi, Komal S.
AU  - Kim, Meen Chul
AU  - Vossough, Arastoo
AU  - Khalili, Nastaran
AU  - Familiar, Ariana
AU  - Gandhi, Deep
AU  - Khalili, Neda
AU  - Kesherwani, Varun
AU  - Haldar, Debanjan
AU  - Anderson, Hannah
AU  - Jin, Run
AU  - Mahtabfar, Aria
AU  - Bagheri, Sina
AU  - Guo, Yiran
AU  - Li, Qi
AU  - Huang, Xiaoyan
AU  - Zhu, Yuankun
AU  - Sickler, Alex
AU  - Lueder, Matthew R.
AU  - Phul, Saksham
AU  - Koptyra, Mateusz
AU  - Storm, Phillip B.
AU  - Ware, Jeffrey B.
AU  - Song, Yuanquan
AU  - Davatzikos, Christos
AU  - Foster, Jessica
AU  - Mueller, Sabine
AU  - Fisher, Michael J.
AU  - Resnick, Adam C.
AU  - Nabavizadeh, Ali
TI  - Multiparametric MRI Along with Machine Learning Informs on Molecular Underpinnings, Prognosis, and Treatment Response in Pediatric Low-Grade Glioma
AID  - 10.1101/2024.04.18.24306046
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.04.18.24306046
4099  - http://medrxiv.org/content/early/2024/05/30/2024.04.18.24306046.short
4100  - http://medrxiv.org/content/early/2024/05/30/2024.04.18.24306046.full
AB  - In this study, we present a comprehensive radiogenomic analysis of pediatric low-grade gliomas (pLGGs), combining treatment-naïve multiparametric MRI and RNA sequencing. We identified three immunological clusters using XCell enrichment scores, highlighting an ‘immune-hot’ group correlating with poorer prognosis, suggesting potential benefits from immunotherapies. A radiomic signature predicting immunological profiles showed balanced accuracies of 81.5% and 84.4% across discovery and replication cohorts, respectively. Our clinicoradiomic model predicted progression-free survival with concordance indices of 0.71 and 0.77 in these cohorts, and the clinicoradiomic scores correlated with treatment response (p = 0.001). We also explored germline variants and transcriptomic pathways related to clinicoradiomic risk, identifying those involved in tumor growth and immune responses. This is the first radiogenomic analysis in pLGGs that enhances prognostication by prediction of immunological profiles, assessment of patients’ risk of progression, prediction of treatment response to standard-of-care therapies, and early stratification of patients to identify potential candidates for novel therapies targeting specific pathways.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by National Institute of Health Grant Fundings 75N91019D00024, Supplement 3U2CHL156291-03S2, and 75N91019D00024.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Children's Brain Tumor Network (CBTN)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes